Go to main content

Department of Haematology

The Department of Haematology is responsible for treatment of all haematological disorders in adults according to internationally accepted guidelines and standards. The department is a centre of expertise for the treatment of blood diseases in Denmark.

About us

The Department of Haematology charter is to provide optimum patient care and as widely as possible, add to the knowledge of the aetiology and pathogenesis of the blood disorders that are treated within the clinic. We aim to develop more effective treatments and to build upon the existing understanding of haematological disorders.

3 specialised units

The department is organized into 3 integrated units which each comprise out-patients, day-care and ward units.

Unit 1: Lymphoma and multiple myeloma responsible for treatment of malignant lymphoma and multiple myeloma.
Unit 2: Allogeneic bone marrow transplantation responsible for the treatment of allogeneic and autologous bone marrow transplantation.
Unit 3: Leukaemia, coagulation and benign blood disorders responsible for the treatment of acute leukaemia, chronic myeloproliferative disorders, chronic lymphatic leukaemia along with non-malignant haematological disorders.

Each unit is led by a management group comprising a specialist doctor, a department nurse and a secretary.

Management

Head of Department

Peter Kampmann
Section 5074

Tel.: 35 45 50 70
E-mail: Peter.Kampmann@regionh.dk

Head Nurse

Hanne Merete Pedersen
Section 5074

Tel.: 35 45 40 83
E-mail: hanne.merete.pedersen.01@regionh.dk

Conditions and treatments

The haematological disorders treated include amongst others:

non malignant blood diseases such as, anaemia and haemostatic disorders
malignant lymphoma
multiple myeloma
acute leukaemias as well as chronic lympho- and myeloproliferative disorders.

The department provides bone marrow transplantations both with the patients own stem cells or with bone marrow from related and unrelated donors.

Research

It is our mission to provide our patients with the best treatment and care, and our research is important for reaching that goal. Through translational research we develop new and more effective treatments, gain new knowledge of blood disease and become better at taking care of our patients.

Chronic Lymphocytic Leukemia Laboratory

Danish Red Blood Cell Center

Grønbæk Group

Contact

Address

Department of Heamatology
Section 4042
Rigshospitalet
Blegdamsvej 9
2100 Copenhagen Ø

Phone

+45 3545 4042

Rigshospitalet recognized among the world’s best hospitals in 2026

The 2026 edition of World’s Best Hospitals, published annually by Newsweek, places two Nordic hospitals among the global top fifteen, with Rigshospitalet – Copenhagen University Hospital at 15th place and Karolinska University Hospital at 4th place worldwide. It is an acknowledgement of the strong tradition for high‑quality, publicly funded healthcare in the Nordic region.

Innovation District Copenhagen appoints new CEO

Innovation District Copenhagen (IDC) has appointed Annemarie Munk Riis as its new Chief Executive Officer, taking up the position on June 1st 2026. She arrives directly from a position as CEO at Green Building Council and holds a degree in economics from the University of Copenhagen and a PhD from Copenhagen Business School.

CollaborationSkåneRH

New Danish–Swedish hospital collaboration to boost research and patient treatment

Conducting large clinical studies and sharing research data between Sweden and Denmark is about to become easier. Rigshospitalet, Copenhagen University Hospital and Skåne University Hospital have signed a Memorandum of Understanding to facilitate cross-border collaboration and strengthen health innovation in the Öresund Region.

Sensory play installations will create a safer hospital experience for children across the country

New play installations at Mary Elizabeths Hospital, Aalborg University Hospital, and Sygehus Lillebælt will help children feel calmer and more confident before medical examinations. Nordea-fonden is funding the project with DKK 12.25 million.

13. January 2026

2025 Highlights from the Phase 1 Unit at Rigshospitalet

In 2025, the Phase 1 Unit at Rigshospitalet continued to strengthen its position as a leading Nordic site for early-phase clinical research, supporting partners and sponsors in the efficient and safe development of innovative therapies.

17. December 2025

Building Europe’s Future Through Collaboration

Explore the report Recommendations for the implementation of the EU Life Science Strategy

3. December 2025

The “Improvement Engine” for the Sickest Patients

After years of preparation, intensive care units across Denmark have begun enrolling patients in the INCEPT platform trial, which tests multiple treatments at once to improve care for the most critically ill.

24. November 2025

ProTarget results presented at ESMO, 2025

ProTarget participated in this year’s ESMO Congress with a poster presentation, sharing results from the first 301 patients enrolled in the trial.

10. November 2025

Comprehensive genomic profiling of CNS tumors reveals rare SETD2 alterations with-out increased mutational burden

SETD2 loss does not confer the same mutational signature in CNS tumors as observed in other tumor types – results presented at AACR-NCI-EORT Molecular Targets and Cancer Therapies congress 2025.

5. November 2025

International award for pioneer in rare diseases

This year’s international research award from Rigshospitalet goes to German professor Heymut Omran. His research has, among other things, paved the way for new treatments and improved diagnostics for patients with a rare respiratory disease.